Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LCTX - Lineage Cell Therapeutics Inc


Close
0.8839
0.007   0.803%

Share volume: 442,000
Last Updated: Fri 30 Aug 2024 10:30:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.88
0.01
0.81%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 0%
Dept financing 9%
Liquidity 56%
Performance 6%
Company vs Stock growth
vs
Performance
5 Days
-6.77%
1 Month
-13.34%
3 Months
-10.61%
6 Months
-15.01%
1 Year
-34.53%
2 Year
-38.19%
Key data
Stock price
$0.88
P/E Ratio 
-6.90
DAY RANGE
$0.84 - $0.92
EPS 
-$0.13
52 WEEK RANGE
$0.77 - $1.61
52 WEEK CHANGE
-$0.34
MARKET CAP 
166.913 M
YIELD 
N/A
SHARES OUTSTANDING 
188.837 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$330,596
AVERAGE 30 VOLUME 
$549,057
Company detail
CEO: Brian Culley
Region: US
Website: http://www.biotimeinc.com/
Employees: 46
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Recent news